In North America, the B subtype of the major group (M) of HIV-1 predominates. Phylogenetic analysis of HIV reverse transcriptase and protease sequences isolated from 479 therapy-naive patients, first seeking treatment in British Columbia between June 1997 and August 1998, revealed a prevalence of 4.4% non-B virus. A range of different subtypes was identified, including one subtype A, 11 C, two D, five CRF01_AE, and one sample that could not be reliably subtyped. Baseline CD4 counts were significantly lower in individuals harbouring the non-B subtypes (P=0.02), but baseline viral loads were similar (P=0.80). In this study, individuals infected with non-B variants did not have a significantly different virological response to therapy after up to 18 months.
References
1.
LeitnerT., KorberB., RobertsonD., GaoF., & HahnB.Updated proposal of reference sequences of HIV-1 genetic subtypes.Human Retroviruses and AIDS 1997: a Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos: Theoretical Biology and Biophysics Group.
2.
KuikenC.L., FoleyB., HahnB., KorberB., McCutchanF., MarxP.A., MellorsJ.W., MullinsJ.I., SodroskiJ., & WolinksyS. (Editors) Human retroviruses and AIDS 1999: A compilation and analysis of nucleic acid and amino acid sequences.Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.
3.
ThompsonM.M., & NájeraR.Travel and the introduction of Human Immunodeficiency Virus type 1 non-B subtype genetic forms into Western Countries. Clinical Infectious Diseases2001; 32: 1732–1737.
4.
PleskoffO., SolN., LabrosseB., & AlizonM.Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin). Journal of Virology1997; 71: 3259–3262.
5.
DorrellL., DongT., OggG.S., ListerS., McAdamS., RostronT., ConlonC., McMichaelA.J., & Rowland-JonesS.L.Distinct recognition of non-clade B Human Immunodeficiency Virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. Journal of Virology1999; 73: 1708–1714.
6.
BuyseyneF., ChaixM-L, RouziouxC., BlancheS., & RivièreY.Patient-specific cytotoxic T-lymphocyte cross-recognition of naturally occurring variants of Human Immunodeficiency Virus Type 1 (HIV-1) p24gag epitope by HIV-1-infected children. Journal of Virology2001; 75: 4941–4946.
7.
Zolla-PaznerS., GomyM.K., & NyambiP.N.The implications of antigenic diversity for vaccine development. Immunology Letters1999; 66: 159–164.
8.
De GrootA., FrostJ., GonzalezM., Saitn-AubinC., SbaiH., SkowronG., & MartinW.“World Clade” vaccine design: selection and confirmation of conserved HIV-1 CTL epitopes using a bioinformatics approach.8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4–8 February 2001, Abstract 195.
9.
TriquesK., CosteJ., PerretJ.L., SegarraC., MpoudiE., ReynesJ., DelaporteE., ButcherA., DreyerK., HermanS., SpadoroJ., & PeetersM.Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. Journal of Clinical Microbiology1999; 37: 110–116.
10.
MichaelN.L., HermanS.A., KwokS., DreyerK., WangJ., ChristophersonC., SpadoroJ.P., YoungK.K., PolonisV., McCutchanF.E., CarrJ., MascolaJ.R., JagodzinskiL.L., & RobbM.L.Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. Journal of Clinical Microbiology1999; 37: 2557–2563.
11.
BestS.J., GustA.P., JohnsonE.I., McGavinC.H., & DaxE.M.Quality of human immunodeficiency virus viral load testing in Australia. Journal of Clinical Microbiology2000; 38: 4015–4020.
12.
AlaeusA., LidmanK., SonnerborgA., & AlbertJ.Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS1997; 11: 859–865.
13.
GrossmanZ., AlkanM., GentwichZ., GottesmanG., HasinD., LeviI., MaayanS., ShaharE., YustI., & SchapiroJ.M.Patterns of drug resistance: Do we need to adjust treatment to clade?8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4–8 February 2001, Abstract 456.
14.
LovedayC., BurkeA., van HooffF., & JohnsonM.Equivalence in virological response to HAART in Patients with HIV-1 subtype non-B infections: a case-controlled study (n=100).8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4–8 February 2001, Abstract 526.
15.
AlaeusA., LiljaE., HermanS., SpadoroJ., WangJ., & AlbertJ.Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay. AIDS Research and Human Retroviruses1999; 15: 889–894.
16.
AlexanderC.S., DongW., SchechterM.T., O'ShaughnessyM.V., StrathdeeS.A., MoT., MontanerJ.S., & HarriganP.R.Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injection drug users. AIDS1999; 13: 981–985.
17.
LarderB.A., KohliA., KellamP., KempS.D., KronickM., & HenfreyR.D.Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature1993; 365: 671–673.
18.
SaitouN., & NeiM.The neighbor-joining method: a new method for reconstructing phylogenetic trees. Molecular Biology and Evolution1987; 4: 406–425.
19.
ThompsonJ.D., GibsonT.J., PlewniakF., JeanmouginF., & HigginsD.G.The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Research1997; 25: 4876–4882.
20.
BrodineS.K., ShafferR.A., StarkeyM.J., TaskerS.A., GilcrestJ.L., LouderM.K., BarileA., VanCottT.C., VaheyM.T., McCutchanF.E., BirxD.L., RichmanD.D., & MascolaJ.R.Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Annals of Internal Medicine1999; 131: 502–506.
21.
WomackC., RothW., NewmanC., RissingJ.P., LovellR., HaburchakD., EssexM., & BondC.Indentification of non-B Human Immunodeficiency Virus type-1 subtypes in rural Georgia. The Journal of Infectious Diseases2001; 183: 138–142.
22.
AlaeusA., LidmanK., BjorkmanA., GieseckeJ., & AlbertJ.Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A–D. AIDS1999; 13: 901–907.
23.
HarriganP.R., MontanerJ.S.G., WegnerS.A., VerbiestW., MillerV., WoodR., & LarderB.A.Worldwide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS2001; 5: 1671–1677.
